Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis

NCT02641457 is registered in ClinicalTrials.gov with Instituto de Olhos de Goiania as lead sponsor.

NCT NCT02641457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02641457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
Lead sponsor
Instituto de Olhos de Goiania
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2014
Completion date
October 31, 2015
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, rubeosis iridis